Shuttle Pharmaceuticals Holdings Inc (NASDAQ: SHPH) is a clinical-stage pharmaceutical company that is pivoting from oncology drug development toward an AI-driven molecular discovery platform. The company generated zero revenue in both FY2025 and FY2024, funding operations entirely through debt and equity financing, including convertible bridge notes and warrant issuances. In November 2025, SHPH acquired substantially all assets of Molecule.ai, a pharmaceutical software company built around an AI platform for molecular discovery and early-stage drug development, while simultaneously winding down clinical trials of its prior lead candidate, Ropidoxuridine. Total research and development expenses were $4.05M in FY2025, up 12% from $3.62M in FY2024. General and administrative expenses rose 307% to $5.67M in FY2025. Cash used in operating activities was $9.48M in FY2025, with cash on hand of $334,005 as of December 31, 2025. The company carries material weaknesses in internal controls over financial reporting as of the filing date.

Revenue model

No revenue as of FY2025 and FY2024. Operations are funded through equity offerings, convertible bridge notes, and warrant issuances. The company is pre-commercial.

Products and services

Molecule.ai platform: an AI-driven molecular discovery and early-stage drug development tool acquired November 21, 2025, built on a unified inference engine and API-first architecture for molecular modeling and predictive analytics. Ropidoxuridine: prior lead oncology drug candidate, clinical trials wound down November 20, 2025.

Customers and end markets

No commercial customers as of FY2025. Target end market is pharmaceutical and biotechnology research, specifically early-stage drug discovery and molecular research.

Value-chain role

Pre-commercial drug discovery and pharmaceutical software developer. Positioned as a technology and drug development company at the research and early-stage development phase of the pharmaceutical value chain.

Geographic exposure

Incorporated and operating in the United States. No international geographic revenue disclosed in the FY2025 10-K filing.

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations Peers: 89bio, Inc. Lineage Cell Therapeutics Inc Kronos Bio, Inc. LianBio MacroGenics Inc Rigel Pharmaceuticals Inc Viking Therapeutics Inc Xoma Royalty Corp